Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adults With Phenylketonuria

NCT04110496•Rubius Therapeutics

View on ClinicalTrials.gov

Summary

This study will evaluate the safety and tolerability of RTX-134 in adult patients with PKU.

Detailed Description

This is a Phase 1b first-in-human trial in adult subjects with PKU. The primary objective of this study is to evaluate the safety and tolerability of RTX-134 following intravenous administration of a single dose. RTX-134 consists of allogeneic human red cells expressing the AvPAL (Anabaena variabilis phenylalanine ammonia lyase) gene inside the cell. The trial is designed to determine a preliminary dose and inform a dosing schedule that is deemed safe, tolerable, and potentially effective. Four dose levels are planned, additional dose levels may be explored. Following administration, subjects will be monitored until 28 days after last detection of RTX-134. Detection of RTX-134 will be evaluated using multiple pharmacokinetic (PK) and pharmacodynamic (PD) assessments including measurement of trans-cinnamic acid (tCA).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18 years or older with:
•1. A clinical diagnosis of PKU, and
•2. Average blood phenylalanine level ≥ 600 µmol/L based on 2 assessments up to 3 weeks apart during the 6-month period before Day 0 (per available data)
•2. Stable diet, including medical formula
•3. Must be a man or a woman not of childbearing potential and agree to use adequate contraception throughout and for one year following study participation.
•4. Adequate organ function
•5. Negative antibody detection on type and screen and no evidence of clinical hemolysis

Exclusion Criteria

•1. Known hypersensitivity to any component of study treatment
•2. Prior treatment with Pegaliase
•3. Start of sapropterin dihydrochloride within 3 weeks of study dosing
•4. Use of an investigational agent within 28 days of study dosing
•5. Concurrent participation in an interventional trial involving ongoing treatment, including placebo.
•6. Infections requiring antimicrobial treatment within 7 days of study dosing
•7. Chronic infections, such as HIV, hepatitis B, or untreated hepatitis C
•8. Conditions that may alter survival of red blood cells, (e.g., autoimmune diseases, splenectomy, etc)
•9. Pregnant or breastfeeding

Locations (1)

Children's Hospital Colorado

Aurora, Colorado, United States

Key Dates

Start Date

January 29, 2020

Primary Completion Date

December 1, 2022

Completion Date

December 1, 2022

Last Updated

December 8, 2022

Enrollment

ACTUAL participants

Conditions

Phenylketonurias

Interventions

RTX-134

DRUG

Development of Novel Psychological Assessment Tools and Anxiety Intervention for Phenylketonuria

NCT06560736

Phenylketonurias

View study

RECRUITINGPHASE1/PHASE2

AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)

NCT06332807

Phenylketonurias

View study

COMPLETEDNA

Evaluation of the Express Plus Range

NCT05051657

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 8, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions